Abstract
Extensive
Extensive
B V Zlokovic, “Clearing amyloid through the blood-brain barrier,” Journal of Neurochemistry, vol. 89, no. 4, pp. 807–811, 2004.
View at: Google ScholarB V Zlokovic, R Deane, J Sallstrom, N Chow, and J M Miano, “Neurovascular pathways and Alzheimer amyloid beta-peptide,” Brain Pathology, vol. 15, no. 1, pp. 78–83, 2005.
View at: Google ScholarB V Zlokovic, “Neurovascular mechanisms of Alzheimer's neurodegeneration,” Trends in Neurosciences, vol. 28, no. 4, pp. 202–208, 2005.
View at: Google ScholarG G Glenner and C W Wong, “Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein,” Biochemical and Biophysical Research Communications, vol. 120, no. 3, pp. 885–890, 1984.
View at: Google ScholarJ Hardy and D J Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.
View at: Google ScholarD Scheuner, C Eckman, M Jensen et al., “Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease,” Nature Medicine, vol. 2, no. 8, pp. 864–870, 1996.
View at: Google ScholarM P Mattson, “Pathways towards and away from Alzheimer's disease,” Nature, vol. 430, no. 7000, pp. 631–639, 2004.
View at: Google ScholarG Evin and A Weidemann, “Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides,” Peptides, vol. 23, no. 7, pp. 1285–1297, 2002.
View at: Google ScholarT E Golde, “The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease,” Brain Pathology, vol. 15, pp. 84–87, 2005.
View at: Google ScholarE A Eckman and C B Eckman, “Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention,” Biochemical Society Transactions, vol. 33, no. pt 5, pp. 1101–1105, 2005.
View at: Google ScholarD Schenk, D Games, and P Seubert, “Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization,” Journal of Molecular Neuroscience, vol. 17, pp. 259–267, 2001.
View at: Google ScholarD Schenk, M Hagen, and P Seubert, “Current progress in beta-amyloid immunotherapy,” Current Opinion in immunology, vol. 16, pp. 599–606, 2004.
View at: Google ScholarD A Bennett and D M Holtzman, “Immunization therapy for Alzheimer disease?” Neurology, vol. 64, pp. 10–12, 2005.
View at: Google ScholarS Howell, J Nalbantoglu, and P Crine, “Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism,” Peptides, vol. 16, pp. 647–652, 1995.
View at: Google ScholarN Iwata, S Tsubuki, Y Takaki et al., “Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition,” Nature Medicine, vol. 6, pp. 143–150, 2000.
View at: Google ScholarN Iwata, S Tsubuki, Y Takaki et al., “Metabolic regulation of brain Abeta by neprilysin,” Science, vol. 292, pp. 1550–1552, 2001.
View at: Google ScholarE A Eckman, D K Reed, and C B Eckman, “Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme,” The Journal of Biological Chemistry, vol. 276, pp. 24540–24548, 2001.
View at: Google ScholarI V Kurochkin and S Goto, “Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme,” FEBS Letters, vol. 345, pp. 33–37, 1994.
View at: Google ScholarJ R McDermott and A M Gibson, “Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme,” Neurochemical Research, vol. 22, pp. 49–56, 1997.
View at: Google ScholarW Q Qiu, D M Walsh, Z Ye et al., “Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation,” The Journal of Biological Chemistry, vol. 273, pp. 32730–32738, 1998.
View at: Google ScholarJ Hu, A Igarashi, M Kamata, and H Nakagawa, “Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity,” The Journal of Biological Chemistry, vol. 276, pp. 47863–47868, 2001.
View at: Google ScholarH Sasaki, Y Saito, M Hayashi, K Otsuka, and M Niwa, “Nucleotide sequence of the tissue-type plasminogen activator cDNA from human fetal lung cells ,” Nucleic Acids Research, vol. 16, no. 12, p. 5692, 1988.
View at: Google ScholarP Verde, S Boast, A Franze, F Robbiati, and F Blasi, “An upstream enhancer and a negative element in the flanking region of the human urokinase plasminogen activator gene,” Nucleic Acids Research, vol. 16, pp. 10699–10716, 1988.
View at: Google ScholarT Yamada, B Kluve-Beckerman, J J Liepnieks, and M D Benson, “In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation,” Scandinavian Journal of Immunology, vol. 41, pp. 570–574, 1995.
View at: Google ScholarH Hamazaki, “Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid protein,” FEBS Letters, vol. 396, pp. 139–142, 1996.
View at: Google ScholarT Yamada, K Miyazaki, N Koshikawa, M Takahashi, H Akatsu, and T Yamamoto, “Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells,” Acta Neuropathologica (Berl), vol. 89, pp. 199–203, 1995.
View at: Google ScholarJ R Backstrom, G P Lim, M J Cullen, and Z A Tokes, “Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40),” The Journal of Neuroscience, vol. 16, pp. 7910–7919, 1996.
View at: Google ScholarK M Carvalho, M S Franca, G C Camarao, and A F Ruchon, “A new brain metalloendopeptidase which degrades the Alzheimer beta-amyloid 1-40 peptide producing soluble fragments without neurotoxic effects,” Brazilian Journal of Medical and Biological Research, vol. 30, pp. 1153–1156, 1997.
View at: Google ScholarS M Saporito-Irwin and W E Van Nostrand, “Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta-protein,” The Journal of Biological Chemistry, vol. 270, pp. 26265–26269, 1995.
View at: Google ScholarS K Rangan, R Liu, D Brune, S Planque, S Paul, and M R Sierks, “Degradation of beta-amyloid by proteolytic antibody light chains,” The Journal of Biochemistry, vol. 42, pp. 14328–14334, 2003.
View at: Google ScholarW Q Qiu, W Borth, Z Ye, C Haass, D B Teplow, and D J Selkoe, “Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex,” The Journal of Biological Chemistry, vol. 271, pp. 8443–8451, 1996.
View at: Google ScholarA J Turner and K Tanzawa, “Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX,” The FASEB Journal, vol. 11, pp. 355–364, 1997.
View at: Google ScholarR Matsas, A J Kenny, and A J Turner, “An immunohistochemical study of endopeptidase-24.11 (“enkephalinase”) in the pig nervous system,” Neuroscience, vol. 18, pp. 991–1012, 1986.
View at: Google ScholarA J Turner, “Neuropeptide signalling and cell-surface peptidases,” Advances in Second Messenger and Phosphoprotein Research, vol. 24, pp. 467–471, 1990.
View at: Google ScholarN Sales, I Dutriez, B Maziere, M Ottaviani, and B P Roques, “Neutral endopeptidase 24.11 in rat peripheral tissues: comparative localization by ‘ex vivo’ and ‘in vitro’ autoradiography,” Regulatory Peptides, vol. 33, pp. 209–222, 1991.
View at: Google ScholarM Letarte, S Vera, R Tran et al., “Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase,” The Journal of Experimental Medicine, vol. 168, pp. 1247–1253, 1988.
View at: Google ScholarT W LeBien and R T McCormack, “The common acute lymphoblastic leukemia antigen (CD10)—emancipation from a functional enigma,” Blood, vol. 73, pp. 625–635, 1989.
View at: Google ScholarN Iwata, M Higuchi, and T C Saido, “Metabolism of amyloid-beta peptide and Alzheimer's disease,” Pharmacology & Therapeutics, vol. 108, pp. 129–148, 2005.
View at: Google ScholarB P Roques, F Noble, V Dauge, M C Fournie-Zaluski, and A Beaumont, “Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology,” Pharmacological Reviews, vol. 45, no. 1, pp. 87–146, 1993.
View at: Google ScholarP E Barker, M A Shipp, L D'Adamio, E L Masteller, and E L Reinherz, “The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27),” Journal of Immunology, vol. 142, pp. 283–287, 1989.
View at: Google ScholarB Malfroy, W J Kuang, P H Seeburg, A J Mason, and P R Schofield, “Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase),” FEBS Letters, vol. 229, no. 1, pp. 206–210, 1988.
View at: Google ScholarM H Lafrance, C Vezina, Q Wang, G Boileau, P Crine, and G Lemay, “Role of glycosylation in transport and enzymic activity of neutral endopeptidase-24.11,” The Biochemical Journal, vol. 302, no. pt 2, pp. 451–454, 1994.
View at: Google ScholarK Barnes, S Doherty, and A J Turner, “Endopeptidase-24.11 is the integral membrane peptidase initiating degradation of somatostatin in the hippocampus,” Journal of Neurochemistry, vol. 64, pp. 1826–1832, 1995.
View at: Google ScholarA J Turner, R E Isaac, and D Coates, “The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function,” BioEssays, vol. 23, pp. 261–269, 2001.
View at: Google ScholarE G Erdos and R A Skidgel, “Human neutral endopeptidase 24.11 (NEP, enkephalinase); function, distribution and release,” Advances in Experimental Medicine and Biology, vol. 240, pp. 13–21, 1988.
View at: Google ScholarE G Erdos and R A Skidgel, “Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones,” The FASEB Journal, vol. 3, pp. 145–151, 1989.
View at: Google ScholarJ C Connelly, R A Skidgel, W W Schulz, A R Johnson, and E G Erdos, “Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 24, pp. 8737–8741, 1985.
View at: Google ScholarM E Pierart, T Najdovski, T E Appelboom, and M M Deschodt-Lanckman, “Effect of human endopeptidase 24.11 (“enkephalinase”) on IL-1-induced thymocyte proliferation activity,” Journal of Immunology, vol. 140, pp. 3808–3811, 1988.
View at: Google ScholarH Akiyama, H Kondo, K Ikeda, M Kato, and P L McGeer, “Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition,” Brain Research, vol. 902, pp. 277–281, 2001.
View at: Google ScholarK Barnes, A J Turner, and A J Kenny, “Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase a (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry,” Journal of Neurochemistry, vol. 58, pp. 2088–2096, 1992.
View at: Google ScholarS Fukami, K Watanabe, N Iwata et al., “Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology,” Neuroscience Research, vol. 43, pp. 39–56, 2002.
View at: Google ScholarN Iwata, Y Takaki, S Fukami, S Tsubuki, and T C Saido, “Region-specific reduction of a beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging,” Journal of Neuroscience Research, vol. 70, pp. 493–500, 2002.
View at: Google ScholarY Takaki, N Iwata, S Tsubuki et al., “Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain,” Journal of Biochemistry (Tokyo), vol. 128, pp. 897–902, 2000.
View at: Google ScholarR A Marr, H Guan, E Rockenstein et al., “Neprilysin regulates amyloid Beta peptide levels,” Journal of Molecular Neuroscience, vol. 22, pp. 5–11, 2004.
View at: Google ScholarY Ji, B Permanne, E M Sigurdsson, D M Holtzman, and T Wisniewski, “Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice,” Journal of Alzheimer's Disease, vol. 3, pp. 23–30, 2001.
View at: Google ScholarH Kanemitsu, T Tomiyama, and H Mori, “Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form,” Neuroscience Letters, vol. 350, pp. 113–116, 2003.
View at: Google ScholarE Hama, K Shirotani, N Iwata, and T C Saido, “Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons,” The Journal of Biological Chemistry, vol. 279, pp. 30259–30264, 2004.
View at: Google ScholarM A Leissring, W Farris, A Y Chang et al., “Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death,” Neuron, vol. 40, pp. 1087–1093, 2003.
View at: Google ScholarM H Mohajeri, K Kuehnle, H Li, R Poirier, J Tracy, and R M Nitsch, “Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease,” FEBS Letters, vol. 562, pp. 16–21, 2004.
View at: Google ScholarR A Marr, E Rockenstein, A Mukherjee et al., “Neprilysin gene transfer reduces human amyloid pathology in transgenic mice,” The Journal of Neuroscience , vol. 23, pp. 1992–1996, 2003.
View at: Google ScholarA Ott, M M Breteler, F van Harskamp et al., “Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study,” British Medical Journal, vol. 310, pp. 970–973, 1995.
View at: Google ScholarH Funato, M Yoshimura, K Kusui et al., “Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease,” The American Journal of Bathology, vol. 152, pp. 1633–1640, 1998.
View at: Google ScholarD W Dickson, H A Crystal, L A Mattiace et al., “Identification of normal and pathological aging in prospectively studied nondemented elderly humans,” Neurobiology of Aging, vol. 13, pp. 179–189, 1992.
View at: Google ScholarJ Apelt, K Ach, and R Schliebs, “Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques,” Neuroscience Letters, vol. 339, pp. 183–186, 2003.
View at: Google ScholarA Caccamo, S Oddo, M C Sugarman, Y Akbari, and F M LaFerla, “Age- and region dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders,” Neurobiology of Aging, vol. 26, pp. 645–654, 2005.
View at: Google ScholarK Yasojima, H Akiyama, E G McGeer, and P L McGeer, “Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide,” Neuroscience Letters, vol. 297, pp. 97–100, 2001.
View at: Google ScholarK Yasojima, E G McGeer, and P L McGeer, “Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain,” Brain Research, vol. 919, pp. 115–121, 2001.
View at: Google ScholarD-S Wang, N Iwata, E Hama, T C Saido, and D W Dickson, “Oxidized neprilysin in aging and Alzheimer's disease brains,” Biochemical and Biophysical Research Communications, vol. 310, pp. 236–241, 2003.
View at: Google ScholarM Maruyama, M Higuchi, Y Takaki et al., “Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease,” Annals of Neurology, vol. 57, no. 6, pp. 832–842, 2005.
View at: Google ScholarM Carpentier, Y Robitaille, L DesGroseillers, G Boileau, and M Marcinkiewicz, “Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy,” Journal of Neuropathology and Experimental Neurology, vol. 61, pp. 849–856, 2002.
View at: Google ScholarS Tsubuki, Y Takaki, and T C Saido, “Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation,” Lancet, vol. 361, no. 9373, pp. 1957–1958, 2003.
View at: Google ScholarD-S Wang, R B Lipton, M J Katz et al., “Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging,” Journal of Neuropathology and Experimental Neurology, vol. 64, pp. 378–385, 2005.
View at: Google ScholarN Macours, J Poels, K Hens, C Francis, and R. Huybrechts, “Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes,” International Review of Cytology, vol. 239, pp. 47–97, 2004.
View at: Google ScholarT Masaki, “Historical review: endothelin,” Trends in Pharmacological Sciences, vol. 25, pp. 219–224, 2004.
View at: Google ScholarD Xu, N Emoto, A Giaid et al., “ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1,” Cell, vol. 78, pp. 473–485, 1994.
View at: Google ScholarA J Turner and L J Murphy, “Molecular pharmacology of endothelin converting enzymes,” Biochemical Pharmacology, vol. 51, pp. 91–102, 1996.
View at: Google ScholarM N Lorenzo, R Y Khan, Y Wang et al., “Human endothelin converting enzyme-2 (ECE2): characterization of mRNA species and chromosomal localization,” Biochimica et Biophysica Acta, vol. 1522, pp. 46–52, 2001.
View at: Google ScholarN Emoto and M Yanagisawa, “Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum,” The Journal of Biological Chemistry, vol. 270, pp. 15262–15268, 1995.
View at: Google ScholarK Shimada, Y Matsushita, K Wakabayashi et al., “Cloning and functional expression of human endothelin-converting enzyme cDNA,” Biochemical and Biophysical Research Communications, vol. 207, pp. 807–812, 1995.
View at: Google ScholarA P Davenport and R E Kuc, “Cellular expression of isoforms of endothelin-converting enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and endothelin-converting enzyme-2,” Journal of Cardiovascular Pharmacology, vol. 36, pp. S12–S14, 2000.
View at: Google ScholarP Korth, R M Bohle, P Corvol, and F Pinet, “Cellular distribution of endothelin converting enzyme-1 in human tissues,” The Journal of Histochemistry and Cytochemistry, vol. 47, pp. 447–462, 1999.
View at: Google ScholarC Pupilli, P Romagnani, L Lasagni et al., “Localization of endothelin-converting enzyme-1 in human kidney,” The American Journal of Physiology, vol. 273, pp. F749–F756, 1997.
View at: Google ScholarK Barnes, L J Murphy, M Takahashi, K Tanzawa, and A J Turner, “Localization and biochemical characterization of endothelin-converting enzyme,” Journal of Cardiovascular Pharmacology, vol. 26, no. suppl 3, pp. S37–S39, 1995.
View at: Google ScholarV Naidoo, S Naidoo, and D M Raidoo, “Immunolocalisation of endothelin-1 in human brain,” Journal of Chemical Neuroanatomy, vol. 27, pp. 193–200, 2004.
View at: Google ScholarB Funalot, T Ouimet, A Claperon et al., “Endothelinconverting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease,” Molecular Psychiatry, vol. 9, pp. 1122–1128, 1059, 2004.
View at: Google ScholarO Valdenaire, E Rohrbacher, and M G Mattei, “Organization of the gene encoding the human endothelin-converting enzyme (ECE-1),” The Journal of Biological Chemistry, vol. 270, pp. 29794–29798, 1995.
View at: Google ScholarO Valdenaire, D Lepailleur-Enouf, G Egidy et al., “A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization,” European Journal of Biochemistry, vol. 264, pp. 341–349, 1999.
View at: Google ScholarK Shimada, M Takahashi, M Ikeda, and K Tanzawa, “Identification and characterization of two isoforms of an endothelin-converting enzyme-1,” FEBS Letters, vol. 371, no. 2, pp. 140–144, 1995.
View at: Google ScholarM Schmidt, B Kroger, E Jacob et al., “Molecular characterization of human and bovine endothelin converting enzyme (ECE-1),” FEBS Letters, vol. 356, no. 2-3, pp. 238–243, 1994.
View at: Google ScholarA Schweizer, O Valdenaire, P Nelbock et al., “Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations,” The Biochemical Journal, vol. 328, no. pt 3, pp. 871–877, 1997.
View at: Google ScholarF Cailler, J P Zappulla, G Boileau, and P Crine, “The N-terminal segment of endothelin-converting enzyme (ECE)-1b contains a di-leucine motif that can redirect neprilysin to an intracellular compartment in Madin-Darby canine kidney (MDCK) cells,” The Biochemical Journal, vol. 341, no. pt 1, pp. 119–126, 1999.
View at: Google ScholarA Azarani, G Boileau, and P Crine, “Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells,” The Biochemical Journal, vol. 333, no. pt 2, pp. 439–448, 1998.
View at: Google ScholarD C Fahnoe, J Knapp, G D Johnson, and K Ahn, “Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH,” Journal of Cardiovascular Pharmacology, vol. 36, no. 5 suppl 1, pp. S22–S25, 2000.
View at: Google ScholarE A Eckman, M Watson, L Marlow, K Sambamurti, and C B Eckman, “Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme,” The Journal of Biological Chemistry, vol. 278, no. 4, pp. 2081–2084, 2003.
View at: Google ScholarW C Duckworth, F B Stentz, M Heinemann, and A E Kitabchi, “Initial site of insulin cleavage by insulin protease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 2, pp. 635–639, 1979.
View at: Google ScholarE S Song, M A Juliano, L Juliano, and L B Hersh, “Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development,” The Journal of Biological Chemistry, vol. 278, no. 50, pp. 49789–49794, 2003.
View at: Google ScholarJ A Affholter, V A Fried, and R A Roth, “Human insulin-degrading enzyme shares structural and functional homologies with E. coli protease III,” Science, vol. 242, no. 4884, pp. 1415–1418, 1988.
View at: Google ScholarJ A Affholter, C L Hsieh, U Francke, and R A Roth, “Insulin-degrading enzyme: stable expression of the human complementary DNA, characterization of its protein product, and chromosomal mapping of the human and mouse genes,” Molecular Endocrinology, vol. 4, no. 8, pp. 1125–1135, 1990.
View at: Google ScholarR 3rd Espinosa, R S Lemons, R K Perlman, W L Kuo, M R Rosner, and M M Le Beau, “Localization of the gene encoding insulin-degrading enzyme to human chromosome 10, bands q23—q25,” Cytogenetics and Cell Genetics, vol. 57, no. 4, pp. 184–186, 1991.
View at: Google ScholarW C Duckworth, R G Bennett, and F G Hamel, “Insulin degradation: progress and potential,” Endocrine Reviews, vol. 19, no. 5, pp. 608–624, 1998.
View at: Google ScholarD J Selkoe, “Clearing the brain's amyloid cobwebs,” Neuron, vol. 32, no. 2, pp. 177–180, 2001.
View at: Google ScholarF Authier, B I Posner, and J J Bergeron, “Insulin-degrading enzyme,” Clinical and Investigative Medicine, vol. 19, pp. 149–160, 1996.
View at: Google ScholarI A Mirsky, S Kaplan, and R H Broh-Kahn, “Persinogen excretion (uropepsin as an index of the influence of various life situations on gastric secretion,” Research Publications - Association for Research in Nervous and Mental Disease, vol. 29, pp. 628–646, 1949.
View at: Google ScholarI V Kurochkin, “Insulin-degrading enzyme: embarking on amyloid destruction,” Trends in Biochemical Sciences, vol. 26, no. 7, pp. 421–425, 2001.
View at: Google ScholarW C Duckworth, R G Bennett, and F G Hamel, “Insulin acts intracellularly on proteasomes through insulin-degrading enzyme,” Biochemical and Biophysical Research Communications, vol. 244, no. 2, pp. 390–394, 1998.
View at: Google ScholarK A Seta and R A Roth, “Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling,” Biochemical and Biophysical Research Communications, vol. 231, no. 1, pp. 167–171, 1997.
View at: Google ScholarK Vekrellis, Z Ye, W Q Qiu et al., “Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme,” The Journal of Neuroscience, vol. 20, no. 5, pp. 1657–1665, 2000.
View at: Google ScholarA Perez, L Morelli, J C Cresto, and E M Castano, “Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains,” Neurochemical Research, vol. 25, no. 2, pp. 247–255, 2000.
View at: Google ScholarW Q Qiu, Z Ye, D Kholodenko, P Seubert, and D J Selkoe, “Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells,” The Journal of Biological Chemistry, vol. 272, no. 10, pp. 6641–6646, 1997.
View at: Google ScholarS Sudoh, M P Frosch, and B A Wolf, “Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells,” Biochemistry, vol. 41, no. 4, pp. 1091–1099, 2002.
View at: Google ScholarW Farris, S Mansourian, Y Chang et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162–4167, 2003.
View at: Google ScholarW Farris, S Mansourian, M A Leissring et al., “Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein,” The American Journal of Pathology, vol. 164, no. 4, pp. 1425–1434, 2004.
View at: Google ScholarH G Bernstein, S Ansorge, P Riederer, M Reiser, L Frolich, and B Bogerts, “Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques,” Neuroscience Letters, vol. 263, no. 2-3, pp. 161–164, 1999.
View at: Google ScholarD G Cook, J B Leverenz, P J McMillan et al., “Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele,” The American Journal of Pathology, vol. 162, no. 1, pp. 313–319, 2003.
View at: Google ScholarJ L Guy, D W Lambert, F J Warner, N M Hooper, and A J Turner, “Membrane-associated zinc peptidase families: comparing ACE and ACE,” Biochimica et Biophysica Acta, vol. 1751, no. 1, pp. 2–8, 2005.
View at: Google ScholarM R Ehlers, E A Fox, D J Strydom, and J F Riordan, “Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 20, pp. 7741–7745, 1989.
View at: Google ScholarL Wei, F Alhenc-Gelas, P Corvol, and E Clauser, “The two homologous domains of human angiotensin I-converting enzyme are both catalytically active,” The Journal of Biological Chemistry, vol. 266, no. 14, pp. 9002–9008, 1991.
View at: Google ScholarB Rigat, C Hubert, F Alhenc-Gelas, F Cambien, P Corvol, and F Soubrier, “An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels,” Journal of Clinical Investigation, vol. 86, no. 4, pp. 1343–1346, 1990.
View at: Google ScholarJ M Saavedra and C Chevillard, “Angiotensin-converting enzyme is present in the subfornical organ and other circumventricular organs of the rat,” Neuroscience Letters, vol. 29, no. 2, pp. 123–127, 1982.
View at: Google ScholarM J McKinley, A L Albiston, A M Allen et al., “The brain renin-angiotensin system: location and physiological roles,” The International Journal of Biochemistry & Cell Biology, vol. 35, no. 6, pp. 901–918, 2003.
View at: Google ScholarP G Kehoe, C Russ, S McIlory et al., “Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease,” Nature Genetics, vol. 21, no. 1, pp. 71–72, 1999.
View at: Google ScholarL A Farrer, T Sherbatich, S A Keryanov et al., “Association between angiotensin-converting enzyme and Alzheimer disease,” Archives of Neurology, vol. 57, no. 2, pp. 210–214, 2000.
View at: Google ScholarJ S Elkins, V C Douglas, and S C Johnston, “Alzheimer disease risk and genetic variation in ACE: a meta-analysis,” Neurology, vol. 62, no. 3, pp. 363–368, 2004.
View at: Google ScholarD J Lehmann, M Cortina-Borja, D R Warden et al., “Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease,” American Journal of Epidemiology, vol. 162, no. 4, pp. 305–317, 2005.
View at: Google ScholarJ W Zhang, X Q Li, Z X Zhang et al., “Association between angiotensin-converting enzyme gene polymorphism and Alzheimer's disease in a Chinese population,” Dementia and Geriatric Cognitive Disorders, vol. 20, no. 1, pp. 52–56, 2005.
View at: Google ScholarH Kolsch, F Jessen, N Freymann et al., “ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia,” Neuroscience Letters, vol. 377, no. 1, pp. 37–39, 2005.
View at: Google ScholarY Narain, A Yip, T Murphy et al., “The ACE gene and Alzheimer's disease susceptibility,” Journal of Medical Genetics, vol. 37, no. 9, pp. 695–697, 2000.
View at: Google ScholarC L Lendon, U Thaker, J M Harris et al., “The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease,” Neuroscience Letters, vol. 328, no. 3, pp. 314–318, 2002.
View at: Google ScholarA Sudilovsky, B Turnbull, S H Croog, and T Crook, “Angiotensin converting enzyme and memory: preclinical and clinical data,” International Journal of Neurology, vol. 21-22, pp. 145–162, 1987.
View at: Google ScholarA J Turner and N M Hooper, “The angiotensin-converting enzyme gene family: genomics and pharmacology,” Trends in Pharmacological Sciences, vol. 23, no. 4, pp. 177–183, 2002.
View at: Google ScholarM L Hemming and D J Selkoe, “Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor,” The Journal of Biological Chemistry, vol. 280, no. 45, pp. 37644–37650, 2005.
View at: Google ScholarN M Barnes, C H Cheng, B Costall, R J Naylor, T J Williams, and C M Wischik, “Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease,” European Journal of Pharmacology, vol. 200, no. 2-3, pp. 289–292, 1991.
View at: Google ScholarE Savaskan, C Hock, G Olivieri et al., “Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia,” Neurobiology of Aging, vol. 22, no. 4, pp. 541–546, 2001.
View at: Google ScholarA Arregui, E K Perry, M Rossor, and B E Tomlinson, “Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas,” Journal of Neurochemistry, vol. 38, no. 5, pp. 1490–1492, 1982.
View at: Google ScholarZ Werb, “ECM and cell surface proteolysis: regulating cellular ecology,” Cell, vol. 91, no. 4, pp. 439–442, 1997.
View at: Google ScholarJ Henkin, P Marcotte, and H C Yang, “The plasminogen-plasmin system,” Progress in Cardiovascular Diseases, vol. 34, no. 2, pp. 135–164, 1991.
View at: Google ScholarS Strickland, A Gualandris, A D Rogove, and S E Tsirka, “Extracellular proteases in neuronal function and degeneration,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 61, pp. 739–745, 1996.
View at: Google ScholarS E Tsirka, A D Rogove, and S Strickland, “Neuronal cell death and tPA,” Nature, vol. 384, no. 6605, pp. 123–124, 1996.
View at: Google ScholarR Madani, S Nef, and J D Vassalli, “Emotions are building up in the field of extracellular proteolysis,” Trends in Molecular Medicine, vol. 9, no. 5, pp. 183–185, 2003.
View at: Google ScholarI B Kingston, M J Castro, and S Anderson, “In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues,” Nature Medicine, vol. 1, no. 2, pp. 138–142, 1995.
View at: Google ScholarS Wnendt, I Wetzels, and W A Gunzler, “Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase,” Thrombosis Research, vol. 85, no. 3, pp. 217–224, 1997.
View at: Google ScholarM D Ledesma, J S Da Silva, K Crassaerts, A Delacourte, B De Strooper, and C G Dotti, “Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains,” EMBO Reports, vol. 1, no. 6, pp. 530–535, 2000.
View at: Google ScholarH M Tucker, M Kihiko-Ehmann, S Wright, R E Rydel, and S Estus, “Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition,” Journal of Neurochemistry, vol. 75, no. 5, pp. 2172–2177, 2000.
View at: Google ScholarM D Ledesma, J Abad-Rodriguez, C Galvan et al., “Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains,” EMBO Reports, vol. 4, no. 12, pp. 1190–1196, 2003.
View at: Google ScholarH M Tucker, M Kihiko-Ehmann, and S Estus, “Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen,” Journal of Neuroscience Research, vol. 70, no. 2, pp. 249–255, 2002.
View at: Google ScholarG A Tennent, L B Lovat, and M B Pepys, “Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 10, pp. 4299–4303, 1995.
View at: Google ScholarH M Tucker, J Simpson, M Kihiko-Ehmann et al., “Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice,” Neuroscience Letters, vol. 368, no. 3, pp. 285–289, 2004.
View at: Google ScholarJ Clarimon, F J Munoz, M Boada et al., “Possible increased risk for Alzheimer's disease associated with neprilysin gene,” Journal of Neural Transmission, vol. 110, no. 6, pp. 651–657, 2003.
View at: Google ScholarS Helisalmi, M Hiltunen, S Vepsalainen et al., “Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 75, no. 12, pp. 1746–1748, 2004.
View at: Google ScholarA Sakai, H Ujike, K Nakata et al., “Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 17, no. 3, pp. 164–169, 2004.
View at: Google ScholarJ D Yang, G Feng, J Zhang et al., “Association between angiotensin-converting enzyme gene and late onset Alzheimer's disease in Han Chinese,” Neuroscience Letters, vol. 295, no. 1-2, pp. 41–44, 2000.
View at: Google ScholarL Bian, J D Yang, T W Guo et al., “Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese,” Neurology, vol. 63, no. 2, pp. 241–245, 2004.
View at: Google ScholarJ Shi, S Zhang, M Tang et al., “Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 60, no. 3, pp. 301–306, 2005.
View at: Google ScholarK Sleegers, T den Heijer, E J van Dijk et al., “ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala,” Neurobiology of Aging, vol. 26, no. 8, pp. 1153–1159, 2005.
View at: Google ScholarL Morelli, R E Llovera, L G Alonso et al., “Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia,” Biochemical and Biophysical Research Communications, vol. 332, no. 3, pp. 808–816, 2005.
View at: Google ScholarL Lilius, C Forsell, K Axelman, B Winblad, C Graff, and L Tjernberg, “No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients,” Neuroscience Letters, vol. 337, no. 2, pp. 111–113, 2003.
View at: Google ScholarA Sakai, H Ujike, K Nakata et al., “No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population,” American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, vol. 125, no. 1, pp. 87–91, 2004.
View at: Google ScholarP Nowotny, A L Hinrichs, S Smemo et al., “Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme,” American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, vol. 136, no. 1, pp. 62–68, 2005.
View at: Google ScholarR Monastero, R Caldarella, M Mannino et al., “Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease,” Neuroscience Letters, vol. 335, no. 2, pp. 147–149, 2002.
View at: Google ScholarM Boussaha, D Hannequin, P Verpillat, A Brice, T Frebourg, and D Campion, “Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease,” Neuroscience Letters, vol. 329, no. 1, pp. 121–123, 2002.
View at: Google ScholarN Sodeyama, H Mizusawa, M Yamada, Y Itoh, E Otomo, and M Matsushita, “Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 71, no. 6, pp. 817–818, 2001.
View at: Google ScholarM A Smith, G Perry, P L Richey et al., “Oxidative damage in Alzheimer's,” Nature, vol. 382, no. 6587, pp. 120–121, 1996.
View at: Google ScholarX Zhu, A K Raina, H G Lee et al., “Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways,” Antioxidants & Redox Signaling, vol. 5, no. 5, pp. 571–576, 2003.
View at: Google ScholarM A Smith, L M Sayre, V M Monnier, and G Perry, “Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles,” Molecular and Chemical Neuropathology, vol. 28, no. 1–3, pp. 41–48, 1996.
View at: Google ScholarK Uchida, “4-Hydroxy-2-nonenal: a product and mediator of oxidative stress,” Progress in Lipid Research, vol. 42, no. 4, pp. 318–343, 2003.
View at: Google ScholarR Russo, R Borghi, W Markesbery, M Tabaton, and A Piccini, “Neprylisin decreases uniformly in Alzheimer's disease and in normal aging,” FEBS Letters, vol. 579, no. 27, pp. 6027–6030, 2005.
View at: Google ScholarH Shinall, E S Song, and L B Hersh, “Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral,” Biochemistry, vol. 44, no. 46, pp. 15345–15350, 2005.
View at: Google ScholarD J Selkoe, “Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease,” Trends in Neurosciences, vol. 16, no. 10, pp. 403–409, 1993.
View at: Google ScholarG D Johnson, T Stevenson, and K Ahn, “Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin,” The Journal of Biological Chemistry, vol. 274, no. 7, pp. 4053–4058, 1999.
View at: Google ScholarM A Leissring, A Lu, M M Condron et al., “Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays,” The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37314–37320, 2003.
View at: Google ScholarA Mukherjee, E Song, M Kihiko-Ehmann et al., “Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques,” The Journal of Neuroscience, vol. 20, no. 23, pp. 8745–8749, 2000.
View at: Google ScholarW E Van Nostrand and M Porter, “Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity,” Biochemistry, vol. 38, no. 35, pp. 11570–11576, 1999.
View at: Google ScholarJ A Carson and A J Turner, “Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?” Journal of Neurochemistry, vol. 81, no. 1, pp. 1–8, 2002.
View at: Google ScholarR Deane, Z Wu, A Sagare et al., “LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms,” Neuron, vol. 43, no. 3, pp. 333–344, 2004.
View at: Google ScholarR Deane, Z Wu, and B V Zlokovic, “RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier,” Stroke, vol. 35, no. 11 suppl 1, pp. 2628–2631, 2004.
View at: Google ScholarR Deane, S Du Yan, R K Submamaryan et al., “RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain,” Nature Medicine, vol. 9, no. 7, pp. 907–913, 2003.
View at: Google Scholar